Glasgow 2024: Double dose start for oral PrEP in new European guidelines – rapid protection in two hours
14 November 2024. Related: Conference reports, Guidelines, HIV prevention and transmission.
Conference reports
Liverpool University Drug Interaction website recognised for global impact on research and care
14 November 2024. Related: Conference reports, PK and drug interactions, Treatment advocacy.
Glasgow 2024: Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48
14 November 2024. Related: Conference reports, Antiretrovirals.
Glasgow HIV Congress 2024
10 November 2024. Related: Early access, Conference reports.
Urgency of planning broad vaccine-like access to lenacapavir PrEP globally
13 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound
9 October 2024. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Lenacapavir PrEP in cisgender gay men, trans and gender-diverse people: results of the PURPOSE 2 study
9 October 2024. Related: Conference reports, HIV prevention and transmission.
HIVR4P 2024: Context of PrEP in Latin America
7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
HIVR4P 2024: Introduction
7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
AIDS 2024: Including people living with HIV in non-HIV research
11 September 2024. Related: Conference reports, Treatment access, Cancer and HIV, Treatment advocacy.
IAS 2024: Open letter to IAS over online access
1 September 2024. Related: Editorial, Conference reports.
AIDS 2024: Ten early reports
12 August 2024. Related: Conference reports, Antiretrovirals.
Five days on two days off: Biktarvy in pilot FOTO study
12 August 2024. Related: Conference reports, Antiretrovirals.
Subcutaneous formulation of long-acting CAB/RPV discontinued
10 August 2024. Related: Conference reports, Antiretrovirals.
First data on third-generation integrase inhibitor from ViiV
10 August 2024. Related: Conference reports, Antiretrovirals.
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study
10 August 2024. Related: Conference reports, Antiretrovirals.
AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more
29 July 2024. Related: Conference reports, HIV prevention and transmission.
Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
26 July 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
AIDS 2024: Introduction to AIDS 2024
22 July 2024. Related: Conference reports.
UNAIDS report: The urgency of now – AIDS at a crossroads.
22 July 2024. Related: Conference reports, Treatment advocacy.
New community call to challenge social settings that drive HIV-related stigma
20 July 2024. Related: Conference reports, HIV prevention and transmission, Treatment advocacy.
HIV research to watch out for at the AIDS 2024 conference
18 July 2024. Related: Conference reports.
CROI 2024 final reports: statins, doxy-PEP and TAF implant
10 June 2024. Related: Conference reports, Coinfections and complications.
Doxy-PEP studies at CROI 2024
9 June 2024. Related: Conference reports, Coinfections and complications.
HIV and statins: REPRIEVE studies at CROI 2024
6 June 2024. Related: Conference reports, Lipodystrophy and metabolic complications.
Challenges with annual TAF implant
5 June 2024. Related: Conference reports, Antiretrovirals.
BHIVA Spring Conference (BHIVA 2024)
2 May 2024. Related: Conference reports.
CROI 2024 now online and open access
10 April 2024. Related: Conference reports.
BHIVA best of CROI webinars now online
4 April 2024. Related: Conference reports.
CROI 2024: Opening lecture calls for scientists to speak up for LGBTQ+ rights in Uganda
24 March 2024. Related: Conference reports, Treatment access, Women's health, Pregnancy, Vaccines and microbicides.
CROI 2024: Pipeline ART – new drugs and formulations
19 March 2024. Related: Conference reports, Antiretrovirals.
CROI 2024: Studies using tecovirimat to treat mpox
16 March 2024. Related: Conference reports, mpox (monkeypox).
CROI 2024: Promising results from first study of long-acting treatment in Africa
10 March 2024. Related: Conference reports, Antiretrovirals, Treatment access.
CROI 2024: HIV studies with semaglutide: significant benefits but limited access for treatment and research
10 March 2024. Related: Conference reports, Lipodystrophy and metabolic complications.
CROI 2024: studies to watch for at this upcoming conference
1 March 2024. Related: Conference reports.
14th International Workshop on HIV and Ageing
1 December 2023. Related: Conference reports, Ageing and life expectancy.
Sarcopenia and mitochondrial dysfunction in people living with HIV: the impact of ageing
1 December 2023. Related: Conference reports, Ageing and life expectancy.
Measuring sarcopenia in people living with HIV
1 December 2023. Related: Conference reports, Ageing and life expectancy.
19th EACS (EACS 2023)
1 December 2023. Related: Conference reports.
EACS 2023: HIV cure-related research
1 December 2023. Related: Conference reports, Cure-related research.
EACS 2023: European guidelines fully revised (October 2023)
1 December 2023. Related: Conference reports, Guidelines.
EACS 2023: Prevalence of doravirine drug resistance in large cohort in British Columbia
1 December 2023. Related: Conference reports, Research studies.
EACS 2023: Switching to daily fixed-dose doravirine/islatravir: 96-week results
1 December 2023. Related: Conference reports, Antiretrovirals.
EACS 2023: TDF/FTC dual-nuke ART: not supported by ALTAR study
1 December 2023. Related: Conference reports, Treatment strategies.
EACS 2023: EATG video campaign against HIV stigma
1 December 2023. Related: Conference reports, Other news, On the web.
12th IAS Conference on HIV Science (IAS 2023): further reports
1 October 2023. Related: Conference reports.
IAS 2023: Lenacapavir studies at IAS: weekly oral dosing and baseline sensitivity in non-clade B settings
1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: LA-CAB/RPV as first-line ART and implementation studies
1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: bNAbs for prevention and cure: antiviral and vaccine-like responses
1 October 2023. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Cure-related research, Vaccines and microbicides.
IAS 2023: High rates of re-suppression with dolutegravir in the ADVANCE study
1 October 2023. Related: Conference reports, Treatment strategies, Drug resistance.
IAS 2023: Bictegravir use in pregnancy: more data needed
1 October 2023. Related: Conference reports, Pregnancy.
IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density
1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
12th IAS Conference on HIV Science (IAS 2023): further reports
1 September 2023. Related: Conference reports.
IAS 2023: Update to navigating the programme and online access
1 September 2023. Related: Conference reports.
IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data
1 September 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
IAS 2023: CHAPAS-4 supports better second-line options for children
1 September 2023. Related: Conference reports, Paediatric care.
IAS 2023: Rapporteur summary Track A – basic science
1 September 2023. Related: Conference reports, Cure-related research, Basic science and immunology, Vaccines and microbicides.
IAS 2023: Rapporteur summary Track C – prevention
1 September 2023. Related: Conference reports, HIV prevention and transmission.
IAS 2023: Rapporteur summary Track D – social and behavioural science
1 September 2023. Related: Conference reports, Treatment strategies.
12th IAS Conference on HIV Science (IAS 2023)
1 August 2023. Related: Conference reports.
IAS 2023: Update to navigate the programme and online access
1 August 2023. Related: Conference reports.
WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load
1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Viral load level when suppressed <1000 predicts future rebound: 3-monthly monitoring required
1 August 2023. Related: Conference reports, HIV prevention and transmission.
ART-associated hypertension can be successfully treated in African settings
1 August 2023. Related: Conference reports, Side effects, Coinfections and complications.
REPRIEVE study: statin benefits people living with HIV at low to moderate CVD risk
1 August 2023. Related: Conference reports, Coinfections and complications.